Open-Source Pharmaceuticals?

"Few companies have demonstrated that they are prepared to commit the time, effort, and resources to embrace a radically different way of operating. Yet the tangible and intangible benefits of adopting new forms of collaboration – reducing the cost of failure, leveraging unused IP and external funding mechanisms, increasing access to networks of talent, and establishing greater trust among patients and other stakeholders – could be extensive. Moreover, these benefits would be realized not only by pharmaceutical companies, but also by academics and other collaborators." Read the opinion piece of Jackie Hunter, CEO of Pharmivation and former Head of Science Environment Development at GlaxoSmithkline, on Project Syndicate here.